ATE150319T1 - Behandlung von asthma - Google Patents

Behandlung von asthma

Info

Publication number
ATE150319T1
ATE150319T1 AT93902914T AT93902914T ATE150319T1 AT E150319 T1 ATE150319 T1 AT E150319T1 AT 93902914 T AT93902914 T AT 93902914T AT 93902914 T AT93902914 T AT 93902914T AT E150319 T1 ATE150319 T1 AT E150319T1
Authority
AT
Austria
Prior art keywords
asthma
treatment
eosinophils
polypeptide
antibody
Prior art date
Application number
AT93902914T
Other languages
English (en)
Inventor
Roy R Lobb
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25234272&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE150319(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of ATE150319T1 publication Critical patent/ATE150319T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
AT93902914T 1992-01-13 1993-01-12 Behandlung von asthma ATE150319T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82176892A 1992-01-13 1992-01-13

Publications (1)

Publication Number Publication Date
ATE150319T1 true ATE150319T1 (de) 1997-04-15

Family

ID=25234272

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93902914T ATE150319T1 (de) 1992-01-13 1993-01-12 Behandlung von asthma

Country Status (9)

Country Link
EP (1) EP0626861B2 (de)
JP (4) JPH07506091A (de)
AT (1) ATE150319T1 (de)
CA (1) CA2127462C (de)
DE (1) DE69309044T3 (de)
DK (1) DK0626861T4 (de)
ES (1) ES2102009T5 (de)
GR (1) GR3023203T3 (de)
WO (1) WO1993013798A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
DE69309487T2 (de) 1992-11-13 1997-10-23 Univ Washington Peripheralisierung hämatopoietischer stammzellen
DE69419721T2 (de) * 1993-01-12 2000-04-27 Biogen, Inc. Rekombinante anti-vla4 antikörpermoleküle
ATE161730T1 (de) * 1993-02-09 1998-01-15 Biogen Inc Antikörper zur behandlung von insulinabhängigen diabetes
AU727187B2 (en) * 1993-02-09 2000-12-07 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
ZA947006B (en) * 1993-09-15 1995-05-02 Univ Emory Method of inhibiting binding of reticulocytes to endothelium by interfering with vla-4/vcam-1 interactions
DE19647382A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
JP2002524529A (ja) 1998-09-14 2002-08-06 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム インテグリンアンタゴニストを用いて多発性骨髄腫および骨髄腫誘導骨吸収を治療する方法
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
PT1173201E (pt) 1999-04-22 2005-08-31 Biogen Idec Inc Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
EP1181054A1 (de) 1999-06-01 2002-02-27 Biogen, Inc. Ein inhibierender monoklonaler antikörper gegen vla-1 und dessen verwendung zur behandlung von entzündungskrankheiten
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE60236735D1 (de) 2001-04-13 2010-07-29 Biogen Idec Inc Antikörper gegen vla-1
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
EP1477482B1 (de) 2002-02-20 2010-04-14 Ajinomoto Co., Inc. Neues phenylalaninderivat
US7345049B2 (en) 2003-12-22 2008-03-18 Ajinomoto Co., Inc. Phenylalanine derivatives
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
PL2034830T3 (pl) 2006-05-25 2015-04-30 Biogen Ma Inc Przeciwciało anty-VLA-1 do leczenia udaru
WO2008103378A2 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
MX2010011145A (es) 2008-04-11 2011-04-11 Merrimack Pharmaceuticals Inc Enlazadores de la albumina de suero humana y conjugados de la misma.
HRP20171045T1 (hr) 2010-04-16 2017-10-06 Biogen Ma Inc. Protutijela anti-vla-4
JP6345123B2 (ja) 2012-02-16 2018-06-20 サンタラス， インコーポレイテッド 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物
CN119080931A (zh) 2018-06-04 2024-12-06 马萨诸塞州渤健公司 具有降低的效应功能的抗vla-4抗体
BR112022014417A2 (pt) 2020-01-24 2022-09-13 Pfizer Anticorpos anti-e-selectina, composições e métodos de uso

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) † 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) † 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL95501A (en) † 1989-09-01 1997-04-15 Hutchinson Fred Cancer Res Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies
DK162890D0 (da) 1990-07-06 1990-07-06 Novo Nordisk As Polypeptid

Also Published As

Publication number Publication date
JPH07506091A (ja) 1995-07-06
JP2003176239A (ja) 2003-06-24
WO1993013798A1 (en) 1993-07-22
ES2102009T3 (es) 1997-07-16
JP2006316070A (ja) 2006-11-24
EP0626861A1 (de) 1994-12-07
DK0626861T4 (da) 2004-08-16
ES2102009T5 (es) 2004-12-16
AU3431793A (en) 1993-08-03
DK0626861T3 (da) 1997-09-22
AU665232B2 (en) 1995-12-21
GR3023203T3 (en) 1997-07-30
HK1007682A1 (en) 1999-04-23
CA2127462A1 (en) 1993-07-22
JP2010285444A (ja) 2010-12-24
JP4590152B2 (ja) 2010-12-01
DE69309044T3 (de) 2004-12-23
EP0626861B1 (de) 1997-03-19
EP0626861B2 (de) 2004-04-28
DE69309044D1 (de) 1997-04-24
DE69309044T2 (de) 1997-09-25
CA2127462C (en) 1999-03-23

Similar Documents

Publication Publication Date Title
ATE150319T1 (de) Behandlung von asthma
ATE161730T1 (de) Antikörper zur behandlung von insulinabhängigen diabetes
DE69227041D1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
PT723538E (pt) Compostos triciclicos de carbamato uteis para a ainibicao da funcao da proteina g e para o tratamento de doencas proliferativas
DE69211403D1 (de) Multifunktionelle wasserdispergierbare Verknüpfungsmittel
ATE168268T1 (de) Behandlung von menschlichen retrovirus- infektionen mit 2',3'-dideoxyinosin
DE68921273D1 (de) System zum kontinuierlichen Behandeln von Halbleitersubstraten.
NO971875D0 (no) Cathepsin 02 protease
ID945B (id) Turunan-turunan baru kroman dan tiokroman
DE59209129D1 (de) Verwendung von Antikörper enthaltenden Präparationen zur Immunsuppression
HUP9900935A2 (hu) Baktériumellenes és gombaellenes hatású peptid és eljárás az előállítására
GR3026519T3 (en) New method of treating depression
FI854383A0 (fi) Foerfarande foer avspaltning av peptider och proteiner av metionyl-bindning.
HUT72187A (en) Recombinant method and host for manufacture of xylitol
ATE220688T1 (de) Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
DE68921229D1 (de) Prozess zur Behandlung von unlöslichem heterogenem Fusionsprotein.
DK0646176T3 (da) Levering og ekspression af et hybridoverfladeprotein på overfladen af grampositive bakterier
DE69029471D1 (de) Wiedergewinnungsverfahren von mikrobiell erzeugtem chymosin
ATE201693T1 (de) Hämoregulierende peptide
DK0383599T3 (da) Protein-anticancermiddel
DK38889A (da) Onkogen-indkodet polypeptid med vaekstfaktoraktivitet
ATE90359T1 (de) Peptide.
DE59310073D1 (de) Verfahren zur Inaktivierung von Viren in Präparationen von Proteinen
IT8819286A0 (it) Procedimento per il trattamento extracorporeo di liquido ascitico.
ATE107165T1 (de) Verwendung von macrolactonen als antiallergica.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification

Ref document number: 0626861

Country of ref document: EP